TABLE 7.
Percent susceptiblea for cefiderocol, ceftazidime-avibactam, eravacycline, and comparator agents by U.S. region among 343 carbapenem-resistant Escherichia coli clinical isolates
| Agentb,c | No. of isolates (%) |
Pd | |||||
|---|---|---|---|---|---|---|---|
| Total U.S. (% of 203) | Central (n = 154) | Northeast (n = 24) | South (n = 15) | Southeast (n = 5) | West (n = 5) | ||
| CFDC | 189 (93) | 144 (94) | 24 (100) | 12 (80) | 5 (100) | 4 (80) | |
| CZA | 186 (92) | 141 (92) | 24 (100) | 12 (80) | 5 (100) | 4 (80) | |
| ERV | 197 (97) | 152 (99) | 23 (96) | 13 (87) | 4 (80) | 5 (100) | 0.01 |
| MEM | 153 (75) | 122 (79) | 15 (62) | 7 (47) | 5 (100) | 4 (80) | 0.02 |
| IPM | 90 (44) | 69 (45) | 24 (100) | 13 (87) | 4 (80) | 3 (60) | <0.001 |
| ETP | 7 (3) | 6 (4) | 1 (4) | 0 (0) | 0 (0) | 0 (0) | |
| GEN | 131 (65) | 108 (70) | 9 (38) | 9 (60) | 2 (40) | 3 (60) | 0.02 |
| TZP | 56 (28) | 50 (33) | 1 (4) | 2 (13) | 3 (60) | 0 (0) | 0.006 |
| AMK | 166 (82) | 129 (84) | 18 (75) | 10 (67) | 4 (80) | 5 (100) | |
| LVX | 40 (20) | 34 (22) | 4 (17) | 1 (7) | 1 (20) | 0 (0) | |
| TGC | 200 (99) | 153 (99) | 24 (100) | 14 (93) | 4 (80) | 5 (100) | 0.003 |
| CAZ | 19 (9) | 142 (92) | 23 (96) | 14 (93) | 1 (20) | 4 (80) | <0.001 |
| MIN | 141 (70) | 105 (68) | 18 (75) | 10 (67) | 4 (80) | 4 (80) | |
a
Values for each agent are expressed as no. of isolates (column %).
b
Abbreviations: AMK, amikacin; CFDC, cefiderocol; CAZ, ceftazidime; CZA, ceftazidime-avibactam; ERV, eravacycline; ETP, ertapenem; GEN, gentamicin; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; MIN, minocycline; TZP, piperacillin-tazobactam; TGC, tigecycline.
c
CL, colistin: not shown; all isolates resistant.
d
P values, as determined by chi-square test, for overall five-group comparisons are shown where P < 0.05.